Table 5.
Summary of clinical responses by lymphoma type or concomitant therapy
| Cohort B: overall responses | ORR n (%) |
CR n (%) |
PR n (%) |
SD n (%) |
PD n (%) |
|---|---|---|---|---|---|
| All patients (n = 25) | 19 (76.0) | 10 (40.0) | 9 (36.0) | 2 (8.0) | 4 (16.0) |
| Responses by individual lymphoma type | |||||
| Diffuse B cell lymphoma (n = 12) | 9 (75.0) | 5 (41.7) | 4 (33.3) | 1 (8.3) | 2 (16.7) |
| Primary CNS lymphoma (n = 8) | 6 (75.0) | 4 (50.0) | 2 (25.0) | 1 (12.5) | 1 (12.5) |
| Mantle cell lymphoma (n = 2) | 2 (100.0) | 0 (0.0) | 2 (100.0) | 0 (0.0) | 0 (0.0) |
| Burkitt’s lymphoma (n = 1) | 1 (100.0) | 1 (100.00) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Lymphoblastic lymphoma (n = 1) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) |
| Primary mediastinal B cell lymphoma (n = 1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) |
| Responses by regimen added concomitantly with liposomal cytarabine | |||||
| WBRT (±low-dose systemic chemotherapy) (n = 12) | 8 (66.6) | 2 (16.6) | 6 (50.0) | 2 (16.6) | 2 (16.6) |
| High-dose CNS-penetrating chemotherapy (n = 6) | 5 (83.3) | 4 (66.6) | 1 (16.7) | 0 (0.0) | 1 (16.7) |
| WBRT + high-dose CNS-penetrating chemotherapy (n = 7) | 6 (85.7) | 4 (57.1) | 2 (28.6) | 0 (0.0) | 1 (14.3) |
CNS central nervous system, CR complete response, ORR objective response rate, PR partial response, PD progressive disease, SD stable disease, WBRT whole brain radiation therapy